Drug Evaluation Committee Questionnaire Report on OSS Usage in FY2024
January 2025
We have compiled the results of a survey on the actual use of the open-source software (OSS) “R” in clinical development operations among member companies of the Data Science Subcommittee, along with our analysis, into the “FY2024 OSS Usage Survey Report.”
The survey results provide insight into the current state of “R” usage in clinical development, changes since a similar survey conducted two years ago, as well as the expectations and challenges identified by each company.
We hope this report will be helpful in your consideration of using open-source software, particularly “R,” within your organization.
Japan Pharmaceutical Manufacturers Association, Drug Evaluation Committee
Data Science Subcommittee, FY2024 Continuing Task Force 11